Drug · CHEMBL522892

DOVITINIB

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. DOVITINIB. Drugs and targets, record CHEMBL522892. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL522892

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: DOVITINIB; ChEMBL
ChEMBL ID: CHEMBL522892; ChEMBL
Type: Small molecule; ChEMBL
Other names: CHIR-258, GFKI-258, NVP-TKI258, TKI-258, Tki-258; ChEMBL
Other form: DOVITINIB LACTATE, CHEMBL4297063; Drugs and targets
DrugBank: DB05928; DrugBank
InChIKey: PIQCTGMSNWUMAF-UHFFFAOYSA-N; ChEMBL
Open Targets' highest stage: Phase 3, for 1 of its 32 diseases, from ClinicalTrials.gov and TTD; Open Targets

Targets8

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

Target	Protein	Mechanism	Action	Gene in Genes
FGFR3	Fibroblast growth factor receptor 3	Fibroblast growth factor receptor 3 inhibitor	INHIBITOR	https://conductscience.org/library/genes/2261
FLT1	Vascular endothelial growth factor receptor	Vascular endothelial growth factor receptor inhibitor	INHIBITOR	https://conductscience.org/library/genes/2321
FLT3	Receptor-type tyrosine-protein kinase FLT3	Tyrosine-protein kinase receptor FLT3 inhibitor	INHIBITOR	https://conductscience.org/library/genes/2322
FLT4	Vascular endothelial growth factor receptor	Vascular endothelial growth factor receptor inhibitor	INHIBITOR	https://conductscience.org/library/genes/2324
KDR	Vascular endothelial growth factor receptor	Vascular endothelial growth factor receptor inhibitor	INHIBITOR	https://conductscience.org/library/genes/3791
KIT	Mast/stem cell growth factor receptor Kit	Stem cell growth factor receptor inhibitor	INHIBITOR	https://conductscience.org/library/genes/3815
PDGFRA	Platelet-derived growth factor receptor	Platelet-derived growth factor receptor inhibitor	INHIBITOR	https://conductscience.org/library/genes/5156
PDGFRB	Platelet-derived growth factor receptor	Platelet-derived growth factor receptor inhibitor	INHIBITOR	https://conductscience.org/library/genes/5159

Source ChEMBL

Diseases32

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
breast cancer	Phase 2	ClinicalTrials.gov	4	4	https://conductscience.org/library/drugs?q=MONDO_0007254
prostate cancer	Phase 2	ClinicalTrials.gov	4	4	https://conductscience.org/library/drugs?q=MONDO_0008315
gastric cancer	Phase 2	ClinicalTrials.gov	3	3	https://conductscience.org/library/drugs?q=MONDO_0001056
gastrointestinal stromal tumor	Phase 2	ClinicalTrials.gov	3	3	https://conductscience.org/library/drugs?q=MONDO_0011719
non-small cell lung carcinoma	Phase 2	ClinicalTrials.gov	3	3	https://conductscience.org/library/drugs?q=MONDO_0005233
plasma cell myeloma	Phase 2	ClinicalTrials.gov	3	3	https://conductscience.org/library/drugs?q=MONDO_0009693
renal cell carcinoma	Phase 3	ClinicalTrials.gov and TTD	3	2	https://conductscience.org/library/drugs?q=MONDO_0005086
adenoid cystic carcinoma	Phase 2	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=MONDO_0004971
cancer	Phase 1	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=MONDO_0004992
colorectal cancer	Phase 2	ClinicalTrials.gov	2	2	https://conductscience.org/library/drugs?q=MONDO_0005575

1 to 10 of 32Source Open Targets

See all 32 diseases

Trials52

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 1 more rests on that reading alone and is shown because the trial's posted result groups or NLM's indexing of its papers name the drug. 6 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT01223027	Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma	Phase 3	564	2015-11-06	dovitinib	Its name	ClinicalTrials.gov
NCT01232296	A Study of Dovitinib Versus Sorafenib in Adult Patients With Hepatocellular Carcinoma (HCC) as a First Line Treatment	Phase 2	162	2015-12-04	dovitinib	Its name	ClinicalTrials.gov
NCT01528345	Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer	Phase 2	97	2016-07-11	dovitinib	Its name	ClinicalTrials.gov
NCT01831726	Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib	Phase 2	80	2017-03-20	dovitinib	Its name	ClinicalTrials.gov
NCT01379534	A Phase II Study to Evaluate the Efficacy of TKI258 for the Treatment of Patients With FGFR2 Mutated or Wild-type Advanced and/or Metastatic Endometrial Cancer	Phase 2	53	2015-03-31	dovitinib	Its name	ClinicalTrials.gov
NCT00831792	TKI258 in Castrate Resistant Prostate Cancer	Phase 2	46	2019-09-11	TKI258	Open Targets' reading, confirmed by the trial's result groups	ClinicalTrials.gov
NCT01478373	Efficacy and Safety of Dovitinib in Patients With Gastrointestinal Stromal Tumors Refractory and/or Intolerant to Imatinib	Phase 2	39	2015-08-10	dovitinib	Its name	ClinicalTrials.gov
NCT01524692	Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma	Phase 2	35	2018-05-07	dovitinib	Its name	ClinicalTrials.gov
NCT01753713	Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma	Phase 2	33	2017-08-08	dovitinib	Its name	ClinicalTrials.gov
NCT01440959	Dovitinib for Imatinib/Sumitinib-failed Gastrointestinal Stromal Tumors (GIST): TKI258	Phase 2	30	2014-03-03	dovitinib	Its name	ClinicalTrials.gov

1 to 10 of 52

See all 52 trials

Comparisons in its trials9

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Dovitinib vs Sorafenib: serious adverse events	133 of 280	112 of 284	564	NCT01223027	Trial comparisons
TKI258 vs Sorafenib: serious adverse events	40 of 79	34 of 83	162	NCT01232296	Trial comparisons
Fulvestrant + Dovitinib Active vs Fulvestrant + Dovitinib Placebo: Number of Participants With Adverse Events as a Measure of Safety	47 of 47	50 of 50	97	NCT01528345	Trial comparisons
Fulvestrant + Dovitinib Active vs Fulvestrant + Dovitinib Placebo: serious adverse events	14 of 47	10 of 50	97	NCT01528345	Trial comparisons
FGFR2 (MUT) vs FGFR2 (WT): serious adverse events	10 of 22	20 of 31	53	NCT01379534	Trial comparisons
Anti-angiogenic Therapy Naive Patients vs Anti-angiogenic Therapy Patients: Arm 1: Progression Free Survival (PFS)	0 of 19	0 of 14	33	NCT01753713	Trial comparisons
Anti-angiogenic Therapy Naive Patients vs Anti-angiogenic Therapy Patients: deaths from any cause	1 of 19	2 of 14	33	NCT01753713	Trial comparisons
Anti-angiogenic Therapy Naive Patients vs Anti-angiogenic Therapy Patients: serious adverse events	10 of 19	7 of 14	33	NCT01753713	Trial comparisons
Dovitinib vs Dovitinib+Fulvestrant: serious adverse events	4 of 10	2 of 2	12	NCT02116803	Trial comparisons

Papers from its trials11

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
25402977	RESULT	1	PubMed
34783716	DERIVED	1	PubMed
29101463	DERIVED	1	PubMed
28213002	DERIVED	1	PubMed
28183331	DERIVED	1	PubMed
25981814	DERIVED	1	PubMed
25457633	DERIVED	1	PubMed
24556040	DERIVED	1	PubMed
23400739	DERIVED	4	PubMed
23010851	DERIVED	1	PubMed

1 to 10 of 11

See all 11 papers from its trials

Tests in its trials0

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL522892

GET https://conductscience.org/api/drugs/v1/CHEMBL522892/diseases?page=2

API reference For AI assistants